How does sipuleucel-T alter our clinical practice?
Publication
, Journal Article
George, D
Published in: BJU Int
October 2010
Duke Scholars
Published In
BJU Int
DOI
EISSN
1464-410X
Publication Date
October 2010
Volume
106
Issue
7
Start / End Page
945 / 946
Location
England
Related Subject Headings
- Urology & Nephrology
- Tissue Extracts
- Randomized Controlled Trials as Topic
- Prostatic Neoplasms
- Male
- Immunotherapy, Active
- Humans
- Cancer Vaccines
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. (2010). How does sipuleucel-T alter our clinical practice? BJU Int, 106(7), 945–946. https://doi.org/10.1111/j.1464-410x.2010.09642.x
George, Daniel. “How does sipuleucel-T alter our clinical practice?” BJU Int 106, no. 7 (October 2010): 945–46. https://doi.org/10.1111/j.1464-410x.2010.09642.x.
George D. How does sipuleucel-T alter our clinical practice? BJU Int. 2010 Oct;106(7):945–6.
George, Daniel. “How does sipuleucel-T alter our clinical practice?” BJU Int, vol. 106, no. 7, Oct. 2010, pp. 945–46. Pubmed, doi:10.1111/j.1464-410x.2010.09642.x.
George D. How does sipuleucel-T alter our clinical practice? BJU Int. 2010 Oct;106(7):945–946.
Published In
BJU Int
DOI
EISSN
1464-410X
Publication Date
October 2010
Volume
106
Issue
7
Start / End Page
945 / 946
Location
England
Related Subject Headings
- Urology & Nephrology
- Tissue Extracts
- Randomized Controlled Trials as Topic
- Prostatic Neoplasms
- Male
- Immunotherapy, Active
- Humans
- Cancer Vaccines
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis